Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of intramuscular autologous bone marrow mononuclear cells in amyotrophic lateral sclerosis
2019-002302-46Phase 2Active
- Sponsor
- Fundación para la Formación e Investigación Sanitaria
- Start
- Aug 2019
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous bone marrow-derived mononuclear cell in amyotrophic lateral sclerosis (ALS), sponsored by Fundación para la Formación e Investigación Sanitaria. Primary endpoint: D50 index from stimulus intensity curves and compound muscle action potential size. Started Aug 2019; status: active.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2019-002302-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002302-46.